<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210929052627N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-10</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of nettle capsules on sexual desire and satisfaction of postmenopausal women</public_title>
      <acronym></acronym>
      <scientific_title>The effect of total nettle capsules on sexual desire and satisfaction of postmenopausal women aged 45-65 years</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/59942</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple
Based on sealed envelopes
The random sequence of the sample is done using random allocation software in two groups A and B. Allocation concealment will be using sealed envelopes. At the beginning of the registration, the entry of the eligible participants will be opened in one of the envelopes and the assigned group will be determined and they will be given capsule A or B based on the assigned group, Blinding description: The subjects, analysts, evaluators, and samplers will be unaware of the intervention and control groups.
The capsules of the intervention group and the placebo group are named groups A and B by the pharmacist consultant, and until the end of the study and analysis, the subjects, researchers and analysts will be unaware of the type of capsules.</study_design>
      <phase>1</phase>
      <hc_freetext>The effect of nettle capsule on sexual desire and satisfaction.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, after obtaining the inclusion criteria and before starting the intervention, first the Halbert sexual orientation and Larson sexual satisfaction questionnaires are filled out and after explaining the study objectives and how to use oral capsules, they are asked to Use nettle capsules containing 500 mg of active ingredient once a week. At the end of week 4, the women fill out the Halbert and Larson questionnaires again, and four weeks after treatment (end of week 8), the Halbert and Larson questionnaire will be completed again. Intervention 2: Control group: They are asked to use nettle extract capsules once a day for 4 weeks. The placebo capsule contains Oisel, which is an inert substance and has no systemic absorption. This capsule is exactly the same in appearance as the intervention. At the end of week 4, women will fill out the Halbert and Larson questionnaires again, and four weeks after treatment (at the end of the eighth week), the Halbert and Larson questionnaires will be filled out again.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
In this study, after blinding patients' private information, all data files will be provided to researchers.

When:
6Months after the results are published

To whom:
Researchers working in academic and scientific institutions, people working in industry

Conditions:
The use of information by individuals will be fully permitted subject to the names of the researchers.
We are also excused from publishing patients' private information.

Where to obtain:
Azam Azarboun
azarbouna982@mums.ac.ir
ID Tele: a.azarboon

How to obtain:
My email will be texted and will be answered within one to two weeks.
AzarbounA982@mums.ac.ir

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azam Azarboun</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Ibn Sina St., Doctoral Crossroads, Mashhad</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>AzarbounA982@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azam Azarboun</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery, Ibn Sina St., Doctoral Crossroads, Mashhad</address>
        <city>mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>AzarbounA982@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At least 12 months after the last menstrual period or follicle-stimulating hormone greater than 40IU
Sexual satisfaction score less than 75 and depression score less than 21, anxiety score less than 20, stress score less than 26 of DASS-21 questionnaire
Menopausal women 65-45 years old
Single spouse
Have at least once or twice a week of normal vaginal intercourse
No chronic diseases (diabetes, hypertension, fat, etc.)
Lack of hormone therapy or consumption of sex hormones during the 8 weeks before the study
No smoking and alcohol
No abnormal uterine bleeding or spotting
Lack of frequent use of other phytoestrogen drugs (soy, red clover, fenugreek, five fingers, fennel) in the past month
Do not take drugs that affect sexual function by the wife or spouse
Absence of known medical and psychological illnesses affecting the sexual function of oneself or one's spouse
Having conscious satisfaction
Iranian nationality
Resident of Mashhad
No history of chemotherapy and pelvic or whole body radiotherapy
No history of sexually transmitted diseases, mastectomy, chlorpuraphy</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>65 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Symptoms of drug allergy
Taking any medication that affects sexual function during the study
Not having sex once a week during the study
Taking hormonal drugs or containing phytoestrogens during research
Experience unfortunate or stressful events in the wife or her husband  while studying
Dissatisfaction with continued cooperation
Do not take the drug for 3 consecutive times or 4 non-consecutive times</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F52</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Sexual dysfunction, not caused by organic disorder or disease  Sexual dysfunction covers the various ways in which an individual is unable to participate in a sexual relationship as he or she would wish. Sexual response is a psychosomatic process and both</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, after obtaining the inclusion criteria and before starting the intervention, first the Halbert sexual orientation and Larson sexual satisfaction questionnaires are filled out and after explaining the study objectives and how to use oral capsules, they are asked to Use nettle capsules containing 500 mg of active ingredient once a week. At the end of week 4, the women fill out the Halbert and Larson questionnaires again, and four weeks after treatment (end of week 8), the Halbert and Larson questionnaire will be completed again.</i_keyword>
      <i_keyword>Control group: They are asked to use nettle extract capsules once a day for 4 weeks. The placebo capsule contains Oisel, which is an inert substance and has no systemic absorption. This capsule is exactly the same in appearance as the intervention. At the end of week 4, women will fill out the Halbert and Larson questionnaires again, and four weeks after treatment (at the end of the eighth week), the Halbert and Larson questionnaires will be filled out again.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sexual desire. Timepoint: Before the study, after the intervention, four weeks after the intervention. Method of measurement: Halbert Questionnaire (HISA)؛This questionnaire consists of 25 questions, which assess the level of sexual desire of the subject. Each item is scored on a Likert scale with 5 degrees. The score range is between 0-100. Higher scores indicate more sexual desire.</prim_outcome>
      <prim_outcome>Sexual satisfaction. Timepoint: Before the study, after the intervention, four weeks after the intervention. Method of measurement: Larson Questionnaire; The scale considered for the analysis according to the score obtained is between 125-25, so that a score less than 50 means sexual dissatisfaction, 75-51 low satisfaction, 76-100 average satisfaction and more Out of 100, it indicates high sexual satisfaction. In this study, people with a sexual satisfaction score of less than 75 are included in the study.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-07</approval_date>
        <contact_name>Ethics committee of Mashhad university of Medical Sciences</contact_name>
        <contact_address>School of Nursing and Midwifery,Ibn Sina St., Ph.D. Intersection,University St. Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
